Background Despite advances in early detection and therapies, cancer is still one of the
most common causes of death worldwide. Since each tumor is unique, there is a need to …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Cell-free DNA (cfDNA) concentrations from patients with cancer are often elevated
compared with those of healthy controls, but the sources of this extra cfDNA have never …

The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …

Through various pathways of cell death, degradation, and regulated extrusion, partial or
complete genomes of various origins (eg, host cells, fetal cells, and infiltrating viruses and …

Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …

Endogenous DNA is primarily found intracellularly in nuclei and mitochondria. However,
extracellular, cell-free (cf) DNA, has been observed in several pathological conditions …

Simple Summary Circulating tumor DNA is DNA released by the tumor into the bloodstream.
In breast cancer, it is used mainly in research or in clinical trials, but it will likely be used in …

Despite advances in screening and therapeutics cancer continues to be one of the major
causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely …

Digital PCR (dPCR) is built on partitioning reagent to the extent that single template
molecules are amplified and visualized individually, whereby offers higher precision and …